Results 221 to 230 of about 8,223,672 (399)
Impact of Positive Lifestyle Behaviors on Direct Health Care Cost Savings for Low Back Pain
Objective This study aimed to investigate the relationship between a previously purpose‐developed lifestyle behavior scale and health care cost savings related to low back pain (LBP). Methods This longitudinal study used data from the Australian Twin Back (AUTBACK) study. LBP and lifestyle behavior measures were collected at baseline. Physical activity
Ye Tian +8 more
wiley +1 more source
The diagnosis of myocardial infarction in the first 16 hours after the onset of chest pain by measurement of log CK slope [PDF]
P J Mullen
openalex +1 more source
Objectives The objectives of this study were to evaluate the correlation and agreement between ultrasound and computed tomography (CT) in measuring ascending aorta diameter in patients with giant cell arteritis (GCA) and to investigate the development of new ascending aortic aneurysms in patients with newly diagnosed GCA. Methods To achieve the primary
Anne C Bull Haaversen +4 more
wiley +1 more source
Measurements of muscle pain, force matching ability and muscle adaptation after eccentric exercise
Nivan Weerakkody
openalex +1 more source
Online questionnaire, clinical and biomechanical measurements for outcome prediction of plantar heel pain: feasibility for a cohort study [PDF]
Halime Gülle +4 more
openalex +1 more source
Objective Ultrasound (US) has been proposed as a potential tool for assessing skin fibrosis in systemic sclerosis (SSc). However, a large‐scale comparison of US‐based assessment with histological markers of skin fibrosis has not been reported. We evaluated the US‐based skin assessments for their face validity (differentiation between involved SSc and ...
Ruhani Desai +12 more
wiley +1 more source
A Preliminary Study of the Objective Measurement of Compliance Rates for Semirigid Lumbar-Support Use in Patients with Chronic Nonspecific Low Back Pain: How Important Is the Compliance Rate? [PDF]
Maryam Hekmatfard +5 more
openalex +1 more source
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech +4 more
wiley +1 more source

